Comparative Pharmacology
Head-to-head clinical analysis: HEMANGEOL versus METOPROLOL TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEMANGEOL versus METOPROLOL TARTRATE.
HEMANGEOL vs METOPROLOL TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hemangeol (propranolol hydrochloride) is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors. In infantile hemangioma, the exact mechanism is not fully understood, but proposed actions include vasoconstriction, inhibition of angiogenesis by downregulating VEGF and bFGF, and induction of apoptosis in endothelial cells.
Competitive beta-1 adrenergic receptor antagonist with weak beta-2 blocking activity; reduces heart rate, contractility, and AV conduction.
3 mg/kg/day orally divided into 2 doses for pediatric patients; adult use not indicated
Initial dose 100 mg daily in divided doses (e.g., 50 mg twice daily) orally; may increase weekly up to 200-450 mg daily in 2-3 divided doses.
None Documented
None Documented
3-4 hours in infants (0-1 year) and 3.5-4.5 hours in children (1-6 years); clinical context: requires TID dosing to maintain therapeutic effect.
3–4 hours (terminal) in healthy adults; prolonged to 7–8 hours in severe hepatic impairment; no change in renal impairment.
Primarily hepatic metabolism via UGT1A9 and CYP2C9; <5% excreted unchanged in urine. Biliary/fecal elimination of metabolites; exact % not defined.
Renal: 95% as metabolites, <5% unchanged. Fecal: negligible.
Category C
Category C
Beta-Blocker
Beta-Blocker